Roche receives European approval for Actemra /RoActemra in giant cell arteritis

Roche announced today that the European Commission (EC) has approved Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. Actemra/RoActemra is the first therapy approved for the treatment of GCA in Europe.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news